The French pharmaceutical giant Ipsen is opening its new accelerator in Boston in April — and it’s already signed its first tenant.

The vaccine startup Affinivax will be moving from LabCentral to the new incubator, at 650 E. Kendall St. in Cambridge, which will open later this spring as long as all the required permits clear, according to new information shared at a Thursday meeting of the Cambridge Biosafety Committee.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy